Abstract Library

#1770 Cytokines as Predictive Factors of Response to Somatostatin Analogues in Patients with Neuroendocrine Tumour

Introduction: The somatostatin analogues are a major therapeutic advance in neuroendocrine tumor (NET) treatment and have multiple modulatory effects on the immune system.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Sciammarella C

Authors: Sciammarella C, Grimaldi A, Circelli L, Modica R, Pizza G,

Keywords: cytokines, neuroendocrine, cell,

#1758 Efficacy and Safety of Low Dose Vandetanib in Metastatic Medullary Thyroid Cancer

Introduction: Medullary thyroid cancer (MTC) is an aggressive thyroid malignancy. Vandetanib is a tyrosine kinase inhibitor approved for locally advanced or metastatic MTC, administered orally 300 mg/daily. Diarrhea, hypertension and QT prolongation are common side effects and may require withdrawal or dose reduction.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Modica R

Authors: Modica R, Pizza G, Lo Calzo F, De Cicco F, Sciammarella C,

Keywords: medullary thyroid cancer, tyrosine kinase inhibitor,

#1756 Somatostatin Analogs in Patients with Multiple Endocrine Neoplasia Type 1 and Zollinger-Ellison Syndrome: Efficacy and Safety

Introduction: Zollinger-Ellison syndrome (ZES) can cause severe complications. In multiple endocrine neoplasia type 1 (MEN1) related ZES, surgery has a controversial role and proton pump inhibitors (PPI) are usually first-line therapy, although some concerns regarding long-term use. Somatostatin analogs (SSA) both reduce hypergastrinemia and have an antiproliferative role.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Modica R

Authors: Modica R, Pizza G, Lo Calzo F, De Cicco F, Sciammarella C,

Keywords: somatostatin analogs, MEN1, Zollinger-Ellison syndrome,

#1191 Efficacy of Lanreotide versus Follow-up in Early-stage Duodeno-Pancreatic Neuroendocrine Tumors (NETs) Related to Multiple Endocrine Neoplasia Type 1 (MEN1): Preliminary Data

Introduction: Surgery is the only curative approach for NETs, representing the first-line therapy. As most pts with MEN1 have multiple duodeno-pancreatic NETs, cure is generally not possible, unless to adopt radical surgery. Somatostatin analogues (SSAs) represent one of the main therapeutic option in functioning well-differentiated NETs. There are no perspective studies focusing on MEN1-related NETs.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Ramundo V

Authors: Ramundo V, Marciello F, Modica R, Marotta V, Pizza G,

Keywords: Multiple Endocrine Neoplasia type 1, Lanreotide, Duodeno-pancreatic NETs.,

#1187 High-Dose Treatment with Somatostatin Analogs in Neuroendocrine Tumors

Introduction: Somatostatin analogs (SSA) effectively control symptoms in neuroendocrine tumours (NET), besides showing antiproliferative activity. In progressive or metastatic NET, increasing SSA dose or shortening the dosing interval are common clinical practice, though empirical.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Modica R

Authors: Modica R, Ramundo V, Marciello F, Marotta V, Pizza G,

Keywords: Somatostatin Analogs, Neuroendocrine Tumors,